DOI:

The latest news from the European Association for Percutaneous Cardiovascular Interventions (EAPCI)

William Wijns*, President EAPCI

As a reader of EuroIntervention Journal, percutaneous cardiovascular intervention must be your primary interest. If so, please take a few moments to read the following update news from your association, the European Association for Percutaneous Cardiovascular Interventions, known as the EAPCI.

EAPCI was formally launched at the World Congress 2006 in Barcelona as a registered branch of the European Society of cardiology. We share the ESC mission, albeit focused on our field of activity:

“To reduce the burden of cardiovascular disease in Europe

through Percutaneous Cardiovascular Interventions”

and the KEYWORDS that govern our action are:

Synergy

Focus

and Credibility.

Even though so recently born, EAPCI is already able to offer you important assets, represented by the heritage of its proud parents (EuroPCR and Working Group 10):

– EuroPCR Course, to take place this year for the first time in Barcelona, on the 22nd-25th May 2007,

– EuroPCRonline.com, featuring outstanding educational content, and the EAPCI website accessible on ESCardio.org,

– Euro Heart Survey and Registry,

– A comprehensive Education-Training-Accreditation programme,

– and not to forget, EuroIntervention Journal itself.

For EAPCI, strengths and opportunities are many. The coalition formed by the EuroPCR team – representing nearly two decades of commitment to education and teaching – along with the European Society of Cardiology – “the” representative cardiovascular medical scientific society in Europe and beyond – is a unique model. The blend of both cultures will materialise strong synergies as we consolidate our current assets and explore new activities.

At a moment where our field is experiencing another wave of expansion, leadership will be needed more than ever. To this end, EAPCI will rely entirely on a close collaboration with the national Working Groups, Societies or other bodies representing interventional communities throughout Europe, as the building blocks of our action. EAPCI can only be successful when governed by a “bottom up” relationship with its constituency.

At the beginning of the three-year term of this Board, many new initiatives are being considered, but at this present time please consider what we already have up and running right now. EAPCI leadership is structured in 8 Committees, each having a well defined mission that will be further delineated on our website and future newsletters: Communication, Euro Heart Survey, Scientific Initiatives, National Membership, Education, Fellowship, Accreditation and Clinical Initiatives. Through your national representatives, you will be asked to join and engage in these various committees, making EAPCI an essential component of your professional life in the years to come.

EAPCI Board 2006-2009.

Rows from left to right and from bottom to top,

– Marc van Sambeek, Keren Deront (EAPCI Office at ESC), Carlo Di Mario (President-Elect),

– Antoine Lafont, Sigmund Silber, Darius Dudek (Secretary),

– Martyn Thomas, Andreas Baumbach, Jean Marco, Jan-Erik Nordrehaug,

– Alberto Cremonesi, Franz Eberli, Horst Sievert (Treasurer), Franz Weidinger, William Wijns (President),

– Bernard Chevalier, Ran Kornowski, Jean Fajadet, Alec Vahanian, Alan Howard (CEO ESC).

Missing on the picture are Sally Vincent (EuroPCR office), Marc Doncieux (CEO Europa) and Patrick Serruys.

Volume 2 Number 4
Feb 20, 2007
Volume 2 Number 4
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-D-26-00648 Jul 20, 2026
When less is no longer more: very early aspirin discontinuation after ACS
Piccolo R and Vitale A
free

Editorial

10.4244/EIJ-E-26-00010 Jul 20, 2026
Aspirin withdrawal after primary PCI for STEMI: timing matters
Paradies V and Mancini G
free

Editorial

10.4244/EIJ-D-26-00715 Jul 20, 2026
Endotype-guided management of ANOCA: are we ready?
Montone R
free

Original Research

10.4244/EIJ-D-26-00148 Jul 20, 2026
Endotype-guided medical therapy and symptom response in ANOCA
Farina J et al

Research Correspondence

10.4244/EIJ-D-25-01215 Jul 20, 2026
Prevalence of vasomotor dysfunction in patients with residual or recurrent angina after percutaneous coronary intervention
Crooijmans C et al

Flashlight

10.4244/EIJ-D-25-00731 Jul 20, 2026
Collapse of a new-generation magnesium scaffold
Bastante T et al
Trending articles
335.05

State-of-the-Art Review

10.4244/EIJ-D-21-00904 Apr 1, 2022
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo D et al
free
84.05

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
49.35

State-of-the-Art

10.4244/EIJ-D-25-00874 Jun 1, 2026
TAVI and coronary interventions: indications, technical considerations, and clinical scenarios
Aquino Bruno H et al
free
45.5

State-of-the-Art

10.4244/EIJ-D-25-01346 May 4, 2026
Slow flow and no reflow after percutaneous coronary intervention
Brugaletta S et al
free
38.2

State-of-the-Art

10.4244/EIJ-D-24-00195 Apr 7, 2025
Percutaneous coronary intervention for calcified and resistant lesions
Pesarini G et al
free
33.15

Original Research

10.4244/EIJ-D-26-00032 May 15, 2026
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial
Fuertes-Kenneally L et al
X

PCR
Impact factor: 9.2
2025 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2026)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2026 Europa Group - All rights reserved